Avandia Again Focus of FDA Review

WASHINGTON (MedPage Today) -- The FDA will review results of the latest "independent readjudication” of the study that formed the basis for its original approval of rosiglitazone (Avandia).
Source: MedPage Today Cardiovascular - Category: Cardiology Source Type: news